Search

Your search keyword '"Chang, Tsung-Yen"' showing total 164 results
Start Over Author "Chang, Tsung-Yen"
164 results on '"Chang, Tsung-Yen"'

7. Refining risk stratification in paediatric B‐acute lymphoblastic leukaemia: Combining IKZF1plus and Day 15 MRD positivity

Author

Liu, Hsi‐Che, primary, Huang, Ying‐Jung, additional, Jaing, Tang‐Her, additional, Wu, Kang‐Hsi, additional, Chen, Shih‐Hsiang, additional, Wang, Shih‐Chung, additional, Yeh, Ting‐Chi, additional, Hsiao, Chih‐Cheng, additional, Chang, Te‐Kau, additional, Yen, Hsiu‐Ju, additional, Huang, Fang‐Liang, additional, Lin, Pei‐Chin, additional, Hou, Jen‐Yin, additional, Sheen, Jiunn‐Ming, additional, Liao, Yu‐Mei, additional, Chang, Tsung‐Yen, additional, Chen, Yu‐Chieh, additional, Chiou, Shyh‐Shin, additional, Yang, Chao‐Ping, additional, Pui, Ching‐Hon, additional, Liang, Der‐Cherng, additional, and Shih, Lee‐Yung, additional

Published
2024
Full Text
View/download PDF

9. Blinatumomab in Children with MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 11 Cases.

Author

Wang, Yi-Lun, Chang, Tsung-Yen, Wen, Yu-Chuan, Yang, Shu-Ho, Hsiao, Yi-Wen, Chiu, Chia-Chi, Chen, Yu-Chieh, Hu, Ruei-Shan, Chen, Shih-Hsiang, Jaing, Tang-Her, and Hsiao, Chih-Cheng

Subjects
*LYMPHOBLASTIC leukemia, *ACUTE leukemia, *HEMATOPOIETIC stem cell transplantation, *CHILD patients, *DISEASE relapse
Abstract

Background/Objectives: Relapsed B-cell acute lymphoblastic leukemia (B-ALL) remains an unresolved matter of concern regarding adverse outcomes. This case study aimed to evaluate the effectiveness of blinatumomab, with or without door lymphocyte infusion (DLI), in treating measurable residual disease (MRD)-positive B-ALL. Methods: All patients who received blinatumomab salvage therapy were included in this study. Eleven patients were included in the study. All patients were evaluated for MRD-negativity. Results: Before starting blinatumomab therapy, seven patients tested positive for MRD, three tested negative, and one had refractory disease. Hematopoietic cell transplantation (HCT) was reserved for five patients with persistent MRD. Six patients became MRD-negative and subsequent HCT was not performed. Only two patients relapsed; one patient died of relapse, and the other one received carfilzomib-based therapy and was MRD-negative thereafter. Nine patients were MRD-negative at a median follow-up of 28 months (15–52 months). Two of three MRD-positive post-transplant patients remained in complete molecular remission after preemptive DLI at the last follow-up date. In the first salvage, blinatumomab may achieve complete remission and bridging to HCT in pediatric patients with end-of-induction MRD-positive B-cell precursor ALL. Conclusions: The decision on how to treat post-transplant relapse continues to affect survival outcomes. Blinatumomab combined with DLI may extend the armamentarium of release options for high-risk pediatric patients. This approach is encouraging for high-risk ALL patients who are MRD-positive post-transplantation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Refining risk stratification in paediatric B‐acute lymphoblastic leukaemia: Combining IKZF1plus and Day 15 MRD positivity.

Author

Liu, Hsi‐Che, Huang, Ying‐Jung, Jaing, Tang‐Her, Wu, Kang‐Hsi, Chen, Shih‐Hsiang, Wang, Shih‐Chung, Yeh, Ting‐Chi, Hsiao, Chih‐Cheng, Chang, Te‐Kau, Yen, Hsiu‐Ju, Huang, Fang‐Liang, Lin, Pei‐Chin, Hou, Jen‐Yin, Sheen, Jiunn‐Ming, Liao, Yu‐Mei, Chang, Tsung‐Yen, Chen, Yu‐Chieh, Chiou, Shyh‐Shin, Yang, Chao‐Ping, and Pui, Ching‐Hon

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, OPTIMISM, OVERALL survival, PEDIATRICS
Abstract

Summary: This study investigates the potential utility of IKZF1 deletion as an additional high‐risk marker for paediatric acute lymphoblastic leukaemia (ALL). The prognostic impact of IKZF1 status, in conjunction with minimal/measurable residual disease (MRD), was evaluated within the MRD‐guided TPOG‐ALL‐2013 protocol using 412 newly diagnosed B‐ALL patients aged 1–18. IKZF1 status was determined using multiplex ligation‐dependent probe amplification. IKZF1 deletions, when co‐occurring with CDKN2A, CDKN2B, PAX5 or PAR1 region deletions in the absence of ERG deletions, were termed IKZF1plus. Both IKZF1 deletion (14.6%) and IKZF1plus (7.8%) independently predicted poorer outcomes in B‐ALL. IKZF1plus was observed in 4.1% of Philadelphia‐negative ALL, with a significantly lower 5‐year event‐free survival (53.9%) compared to IKZF1 deletion alone (83.8%) and wild‐type IKZF1 (91.3%) (p < 0.0001). Among patients with Day 15 MRD ≥0.01%, provisional high‐risk patients with IKZF1plus exhibited the worst outcomes in event‐free survival (42.0%), relapse‐free survival (48.0%) and overall survival (72.7%) compared to other groups (p < 0.0001). Integration of IKZF1plus and positive Day 15 MRD identified a subgroup of Philadelphia‐negative B‐ALL with a 50% risk of relapse. This study highlights the importance of assessing IKZF1plus alongside Day 15 MRD positivity to identify patients at increased risk of adverse outcomes, potentially minimizing overtreatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. A case series and literature review on 98 pediatric patients of germ cell tumor developing growing teratoma syndrome

Author

Hiseh, Ming‐Yun, primary, Chen, Hsin‐Hung, additional, Lee, Chih‐Ying, additional, Hung, Giun‐Yi, additional, Chang, Tsung‐Yen, additional, Chen, Shih‐Hsiang, additional, Lai, Jin‐Yao, additional, Jaing, Tang‐Her, additional, Cheng, Chao‐Neng, additional, Chen, Jiann‐Shiuh, additional, Tsai, Hsin‐Lin, additional, Yu, Ting‐Yen, additional, Hou, Ming‐Hsin, additional, Ho, Cheng‐Yin, additional, and Yen, Hsiu‐Ju, additional

Published
2023
Full Text
View/download PDF

27. A case series and literature review on 98 pediatric patients of germ cell tumor developing growing teratoma syndrome.

Author

Hsieh, Ming‐Yun, Chen, Hsin‐Hung, Lee, Chih‐Ying, Hung, Giun‐Yi, Chang, Tsung‐Yen, Chen, Shih‐Hsiang, Lai, Jin‐Yao, Jaing, Tang‐Her, Cheng, Chao‐Neng, Chen, Jiann‐Shiuh, Tsai, Hsin‐Lin, Yu, Ting‐Yen, Hou, Ming‐Hsin, Ho, Cheng‐Yin, and Yen, Hsiu‐Ju

Subjects
CHILD patients, LITERATURE reviews, GERM cell tumors, TERATOMA, SURVIVAL rate, CANCER cells
Abstract

Introduction: Malignant germ cell tumors (MGCTs) can develop either extracranially or intracranially. Growing teratoma syndrome (GTS) may develop in these patients following chemotherapy. Reports on the clinical characteristics and outcomes of GTS in children with MGCTs are limited. Methods: We retrospectively collected the data, including the clinical characteristics and outcomes of five patients in our series and 93 pediatric patients selected through a literature review of MGCTs. This study aimed to analyze survival outcomes and risk factors for subsequent events in pediatric patients with MGCTs developing GTS. Results: The sex ratio was 1.09 (male/female). In total, 52 patients (53.1%) had intracranial MGCTs. Compared with patients with extracranial GCTs, those with intracranial GCTs were younger, predominantly boys, had shorter intervals between MGCT and GTS, and had GTS mostly occurring over the initial site (all p < 0.001). Ninety‐five patients (96.9%) were alive. However, GTS recurrence (n = 14), GTS progression (n = 9), and MGCT recurrence (n = 19) caused a substantial decrease in event‐free survival (EFS). Multivariate analyses showed that the only significant risk factors for these events were incomplete GTS resection and different locations of GCT and GTS. Patients without any risk had a 5‐year EFS of 78.8% ± 7.8%, whereas those with either risk had 41.7% ± 10.2% (p < 0.001). Conclusion: For patients with high‐risk features, every effort should be made to closely monitor, completely remove, and pathologically prove any newly developed mass to guide relevant treatment. Further studies incorporating the risk factors into treatment strategies may be required to optimize adjuvant therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Pediatric acute lymphoblastic leukemia with t(1;19)/TCF3-PBX1in Taiwan

Author

Yen, Hsiu-Ju, primary, Chen, Shih-Hsiang, additional, Chang, Tsung-Yen, additional, Yang, Chao-Ping, additional, Lin, Dong-Tsamn, additional, Hung, Iou-Jih, additional, Lin, Kai-Hsin, additional, Chen, Jiann-Shiuh, additional, Hsiao, Chih-Cheng, additional, Chang, Tai-Tsung, additional, Chang, Te-Kao, additional, Peng, Ching-Tien, additional, Lin, Ming-Tsan, additional, Jaing, Tang-Her, additional, Liu, Hsi-Che, additional, Jou, Shiann-Tarng, additional, Lu, Meng-Yao, additional, Cheng, Chao-Neng, additional, Sheen, Jiunn-Ming, additional, Chiou, Shyh-Shin, additional, Hung, Giun-Yi, additional, Wu, Kang-Hsi, additional, Yeh, Ting-Chi, additional, Wang, Shih-Chung, additional, Chen, Rong-Long, additional, Chang, Hsiu-Hao, additional, Yang, Yung-Li, additional, Chen, Shu-Huey, additional, Cheng, Shin-Nan, additional, Chang, Yu-Hsiang, additional, Chen, Bow-Wen, additional, Hsieh, Yuh-Lin, additional, Huang, Fang-Liang, additional, Ho, Wan-Ling, additional, Wang, Jinn-Li, additional, Chang, Chia-Yau, additional, Chao, Yu-Hua, additional, Lin, Pei-Chin, additional, Chen, Yu-Chieh, additional, Liao, Yu-Mei, additional, Lin, Tung-Huei, additional, Shih, Lee-Yung, additional, and Liang, Der-Cherng, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results